Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jason Zhu

Characterization of Tumor Mutation Burden, PD-L1 and DNA Repair Genes to Assess Relationship to Immune Checkpoint Inhibitors Response in Metastatic Renal Cell Carcinoma

Journal for ImmunoTherapy of Cancer

English

Related publications

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

English

PD-L1 Expression in Basaloid Squamous Cell Lung Carcinoma: Relationship to PD-1+ and CD8+ Tumor-Infiltrating T Cells and Outcome

English

Metastatic Clear Cell Renal Cell Carcinoma With a Long-Term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression

Clinical Genitourinary Cancer

Oncology

Urology

2019

English

Response to Nivolumab in Metastatic Collecting Duct Carcinoma Expressing PD‑L1: A Case Report

Molecular and Clinical Oncology

Cancer Research

Oncology

2017

English

Nuclear IRF-1 Expression as a Mechanism to Assess “Capability” to Express PD-L1 and Response to PD-1 Therapy in Metastatic Melanoma

Journal for ImmunoTherapy of Cancer

English

P1.04-17 Tumour Burden as a Predictive Tool of Response to Immune Checkpoint Inhibitors (ICI) in Patients With Metastatic Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology

English

First-Line Immune Checkpoint Therapy in Metastatic Squamous Cell Lung Cancer Harboring Both EGFR Mutation and High Expression of PD-L1: A Case Report

English

P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients With Lung Cancer

Journal of Thoracic Oncology

English

PD-L1 Inhibition With Avelumab for Metastatic Merkel Cell Carcinoma

Expert Review of Clinical Pharmacology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Jason Zhu

Characterization of Tumor Mutation Burden, PD-L1 and DNA Repair Genes to Assess Relationship to Immune Checkpoint Inhibitors Response in Metastatic Renal Cell Carcinoma

Related publications

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

PD-L1 Expression in Basaloid Squamous Cell Lung Carcinoma: Relationship to PD-1+ and CD8+ Tumor-Infiltrating T Cells and Outcome

Metastatic Clear Cell Renal Cell Carcinoma With a Long-Term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression

Response to Nivolumab in Metastatic Collecting Duct Carcinoma Expressing PD‑L1: A Case Report

Nuclear IRF-1 Expression as a Mechanism to Assess “Capability” to Express PD-L1 and Response to PD-1 Therapy in Metastatic Melanoma

P1.04-17 Tumour Burden as a Predictive Tool of Response to Immune Checkpoint Inhibitors (ICI) in Patients With Metastatic Non-Small-Cell Lung Cancer

First-Line Immune Checkpoint Therapy in Metastatic Squamous Cell Lung Cancer Harboring Both EGFR Mutation and High Expression of PD-L1: A Case Report

P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients With Lung Cancer

PD-L1 Inhibition With Avelumab for Metastatic Merkel Cell Carcinoma